Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04168502
Title Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Gruppo Italiano Malattie EMatologiche dell'Adulto
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin + Glasdegib

Gemtuzumab ozogamicin

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST